DIRAS3 Antikörper (AA 131-229)
Kurzübersicht für DIRAS3 Antikörper (AA 131-229) (ABIN681448)
Target
Alle DIRAS3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 131-229
-
Homologie
- Human
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human ARHI
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- DIRAS3 (DIRAS Family, GTP-Binding RAS-Like 3 (DIRAS3))
-
Andere Bezeichnung
- ARHI
-
Hintergrund
-
Synonyms: ARHI, NOEY2, GTP-binding protein Di-Ras3, Distinct subgroup of the Ras family member 3, Rho-related GTP-binding protein RhoI, DIRAS3, RHOI
Background: ARHI contains a highly conserved GTP-binding domain, a putative effector domain distinct from that of RAS and RAP proteins, and a C-terminal membrane localization motif. ARHI mRNA is detected in all normal breast and ovarian epithelial cell cultures tested, as well as in normal ovary, heart, liver, pancreas and brain however ARHI expression is down-regulated in breast and ovarian tumors. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3.
-
Gen-ID
- 9077
-
UniProt
- O95661
Target
-